by William Faloon
Echogram, axial section: tumor of a patient with prostate cancer.
The acronym PSA stands for prostate-specific antigen, the most abundant protein synthesized in the prostate gland. Men have their blood tested for PSA in order to detect prostate cancer at an early stage when it is often curable. The PSA test can also help assess the efficacy of various prostate cancer treatments.
Until now, PSA has been viewed only as a blood indicator of prostate cancer, infection, or inflammation. Emerging evidence, however, reveals that PSA may be more than just a marker of prostate health. It appears that PSA itself may play a role in the progression and metastasis of prostate cancer,1-3 thus opening up new therapeutic pathways for preventing and treating this epidemic disease.
A significant amount of published data associates high intake of certain nutrients with reduced incidences of prostate cancer.4-12 A few studies suggest that these same nutrients may even help control advanced stages of the disease.13,14
Scientists are now finding that some of these nutrients function to reduce or interfere with PSA activity in the prostate gland. With new data suggesting that PSA itself may be involved in the progression and spread of prostate cancer, the anti-PSA activity of these nutrients becomes significant and helps explain why men who consume certain nutrients have lower incidences of the disease and a slower progression of disease when prostate cancer has been diagnosed.
Staggering Statistics on Prostate Cancer
Cells in the prostate gland are very prone to gene mutation, while other tissues in the same anatomical region, such as the seminal vesicles, develop primary cancers at a significantly lower rate.15
Autopsy evidence indicates that prostate cancer is histologically evident in up to 34% of men aged 40-49 and up to 70% of men aged 80 and older.16,17 Most men, however, never progress to clinically diagnosed disease, indicating the presence of control mechanisms that keep prostate cancer cell colonies small and thus controlled.
It now appears possible to partially regulate some of the genes that ordinarily enable cells to divide out of control and eventually form a prostate tumor, which may then proliferate, invade, and metastasize. These new findings make it more important than ever for men to monitor their blood PSA levels to detect prostate cancer at its earliest stages.
Treating Advanced Prostate Cancer with Lycopene
Cancer confined to the prostate gland is usually curable.18-23 The medical literature indicates, however, that untreated prostate cancer leads to continued growth of the tumor cell population. This greater tumor burden is associated with genetic mutation that is likely responsible for the development of hormone-insensitive prostate cancer.24-27 Once prostate cells mutate into aggressive hormone-refractory forms that escape into the body, metastatic prostate cancer usually is diagnosed and the patient faces a grueling battle to survive.
In a study of 20 patients with metastatic hormone-refractory prostate cancer, each patient received 10 mg a day of lycopene for three months.14 No other treatment was given. One patient achieved a complete response, defined as a reduction of PSA (to under 4 ng/ml) and the absence of any sign of the disease for eight weeks. Six patients (30%) had a partial response, defined as a 50% reduction in PSA and alleviation of other symptoms such as bone pain if present. The disease remained stable in 10 patients (50%) and progressed in three (15%). A remarkable 63% (10 of 16) with bone pain were able to reduce their daily use of pain-suppressing drugs. The study concluded, “Lycopene therapy appears to be effective and safe in the treatment of hormone-refractory prostate cancer.”
In another study of 54 metastatic prostate cancer patients, half (27) were castrated, while the other half were castrated and given 2 mg of lycopene twice daily.13 Castration (removal of the testes) reduces testosterone levels and is a treatment for those with androgen-dependent prostate cancer. After six months, PSA declined significantly in both groups, but more so in the group receiving lycopene. After two years, 40% of the castrated group had a PSA reduction of less than 4 ng/ml, compared to 78% in the lycopene group. Bone scans showed that twice as many patients in the lycopene-plus-castration group attained a complete response compared to the castration-only men.
The author concluded, “Adding lycopene to orchidectomy (castration) produced a more reliable and consistent decrease in serum PSA level; it not only shrinks the primary tumor but also diminishes the secondary tumors, providing better relief from bone pain and lower urinary tract symptoms, and improving survival compared with orchidectomy alone.” What is impressive about these two studies is that only small doses of lycopene (4-10 mg/day) were used. That low doses of lycopene produced such favorable results in these late-stage prostate cancer patients is quite remarkable and worthy of further study.
Lycopene Reduces Prostate Cell DNA Damage
Because cancer is initiated and promoted as the result of ongoing DNA damage, researchers conducted a study to evaluate the genomic effects of lycopene in men with localized disease. For three weeks, a group of 32 men consumed tomato sauce each day supplying 30 mg of lycopene. Prostate tissue was obtained initially at biopsy and then again after surgical removal of the prostate gland.28 After three weeks, PSA levels declined by 17.5% and a blood marker of DNA damage fell by 21.3%. An analysis of the prostate tissues showed that the lycopene-supplemented patients had major reductions in many of the DNA factors that usually favor uncontrolled prostate cancer cell propagation. Moreover, in the lycopene-supplemented patients, prostate cancer cells as well as hyperplastic prostatic tissue showed an increase in apoptosis (programmed cell death). This study showed that prostate cells readily take up lycopene, with cellular lycopene levels increasing 2.92-fold after only three weeks. This increase in lycopene correlated with a significant reduction of DNA damage in prostate tissue.
X-ray of hip showing prostate cancer.
Boron Shrinks Prostate Tumors, Reduces PSA in Mice
As noted earlier, most doctors regard PSA solely as a useful laboratory marker for diagnosing prostate cancer. At a cellular level, however, PSA functions as an active growth factor in the prostate gland. One such mechanism involves PSA’s enzymatic ability to degrade extracellular matrix (structural support) proteins such as fibronectin and laminin.1 This action of PSA may promote tumor growth and metastasis. Another potential tumor-promoting action of PSA involves freeing insulin-like growth factor 1 (IGF-1) from its binding protein (BP-3), providing increased local levels of IGF-1, leading to tumor growth.2,3 To understand the nature of our enemy—the cancer cell—we must realize that the tumor cell is functional and produces cell products that favor its growth, invasiveness, and spread!
Studies by Gallardo-Williams and colleagues have shown that boric acid and boronic acid significantly inhibit the degradation of fibronectin by enzymatically active PSA.1 In another study in mice, the same authors used immunohistochemistry staining of tissues to show that expression of IGF-1 in tumors was markedly reduced by boric acid. In response to both low- and high-dose boron supplementation, PSA levels plummeted by an average of 87%, while tumor size declined by 31.5% on average. Also noted was a significantly lower incidence of mitotic figures in the boron-supplemented groups. Mitotic figures reflect DNA synthesis and proliferative activity.29
Consistent with these findings, a recent study showed that boron inhibited the proliferation of prostate cancer cell lines DU-145 (an androgen-independent line) and LNCaP (an androgen-dependent cell line) in a dose-dependent manner.30 These animal and cell line studies appear to be relevant to humans, based on a report from UCLA in which Cui and colleagues showed that men with the highest dietary boron intake reduced their prostate cancer risk by 54% compared to men with the lowest boron intake! While the authors noted that the observed association should be interpreted with caution because of the small case sample size and the nature of the cross-sectional study design, clearly these findings deserve further investigation. If the above-cited animal studies can be replicated in human patients, boron at doses ranging from 6 to 15 mg a day may become an effective and very low-cost adjuvant therapy.12
Hidden Dangers of PSA
Because PSA may contribute not only to prostate cancer progression but also to the ability of these cells to escape the prostate and metastasize to distant sites within the body, we can no longer think of PSA as merely a blood marker reflecting prostate health.
In fact, many, if not all, of the biomarkers used in tracking a wide array of cancers may have specific cancer-facilitating properties. Therefore, in men with prostate cancer, and perhaps even in those trying to prevent the emergence of prostate cancer, taking steps to keep PSA levels low may reduce one’s risk of developing this illness or having it progress to a clinically symptomatic condition.
The easiest way to reduce PSA levels by half is to inhibit the enzyme 5-alpha reductase, which transforms testosterone into the more androgenic dihydrotestosterone (DHT). DHT has a growth-promoting effect on prostate cells that is significantly greater than that of testosterone. In the peer-reviewed literature, this differential effect of DHT on prostate cell growth is 2.4-10 times greater.31-33
The most effective DHT-lowering prescription drug is Avodart®. Unlike the more popular Proscar® that inhibits only type 2 5-alpha reductase, Avodart® blocks both type 1 and type 2 5-alpha reductase, thus reducing blood DHT levels by 93%. Using a 5-mg dose of Avodart®—10 times that routinely prescribed for BPH—Andriole and colleagues demonstrated a 97% reduction of intra-prostatic DHT.34 Lazier and colleagues found that Avodart® inhibited DHT-induced secretion of PSA as well as cancer cell proliferation, and that at higher doses, Avodart® resulted in cancer cell death in both androgen-dependent (LNCaP) and androgen-indepen-dent (PC-3) cell lines.35
Such findings are pertinent to human clinical trials of Avodart®. In a study of 4,325 men with benign prostate enlargement who were randomly selected to receive either Avodart® (0.5 mg/day) or placebo, those receiving Avodart® had a cumulative incidence of prostate cancer of 1.2% compared to 2.5% for the placebo group at 27 months of follow-up. This equates with a 52% reduction in prostate cancer in the Avodart® group.36 In another study using Proscar®, 18,882 men aged 55 or older (with normal digital rectal examination results and a PSA level of 3.0 ng/ml or lower) were randomly assigned treatment with Proscar® (5 mg/day) or placebo for seven years. Prostate cancer was detected in 803 of the 4,368 men in the Proscar® group and 1,147 of the 4,692 men in the placebo group, for a 24.8% reduction in prevalence over seven years. High-grade cancers were noted in 6.4% of Proscar®-treated patients compared to 5.1% of men receiving placebo.37 (As noted earlier, Proscar® suppresses only type 2 5-alpha reductase, whereas Avodart® blocks both type 1 and type 2 5-alpha reductase. Avodart® thus appears to be the better drug.)